论文部分内容阅读
目的评价曲美他嗪对冠心病合并糖尿病经皮冠状动脉介入治疗(PCI)术后患者再发心绞痛的干预作用。方法将60例冠心病合并糖尿病PCI术后再发心绞痛患者随机分为常规治疗组和曲美他嗪组,进行相关对比研究。结果两组治疗4周后,心绞痛发作频率、持续时间较治疗前均明显减少(P<0.05),曲美他嗪组更明显,而且无明显不良反应,血糖稳定,两组间的心率、血压比较差异无统计学意义(P>0.05)。结论曲美他嗪可明显减少冠心病合并糖尿病PCI术后患者心绞痛发作次数及持续时间,改善心功能,且血糖稳定,对心率、血压无影响,安全有效。
Objective To evaluate the effect of trimetazidine on angina pectoris in patients with coronary heart disease complicated with percutaneous coronary intervention (PCI). Methods Sixty patients with angina pectoris after coronary angiography and diabetes mellitus were randomly divided into routine treatment group and trimetazidine group. Results After 4 weeks of treatment, the frequency and duration of angina pectoris in both groups were significantly lower than those before treatment (P <0.05). Trimetazidine group was more obvious with no obvious adverse reactions, blood glucose was stable, heart rate and blood pressure The difference was not statistically significant (P> 0.05). Conclusion Trimetazidine can reduce the number and duration of angina pectoris patients with coronary heart disease and diabetes mellitus after PCI, improve cardiac function, maintain stable blood glucose level, have no effect on heart rate and blood pressure, and be safe and effective.